Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Schur Pharmazeutika GmbH & Co. KG was a German pharmaceutical company based in Düsseldorf that specialized in the development and distribution of specialty medications, particularly in the areas of trauma care, gynecology, and urology. The company's portfolio featured products such as Chomelanum (choline stearate), a topical ointment used to treat sports injuries and swelling, and Vagicillin (neomycin sulfate), an antibiotic for vaginal infections. Other notable products included Cysto-Myacyne N for the treatment of cystitis via bladder instillation. The company entered liquidation in 2015 and was officially deleted from the commercial register in 2024. Throughout its operation, it focused on providing niche therapeutic solutions for the German healthcare market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Schur Pharmazeutika.